



Reengineering the art of EVAR



14 French Ultra-low profile



Customisable
tri-modular design




Efficacy and durability
without compromise¹




Few units fit most anatomies

**Demonstrated
in *standard*
and complex
anatomies.** ^{2,3,5}

Reengineering the EVAR you know



From catheter to crown, the ultra-low profile INCRRAFT™ System has been designed to enhance EVAR success—including your most complex cases.²



...Crafted for simplified navigation

- ▶ **Highly flexible, hydrophilically coated catheter** helps minimise delivery-related complications by advancing smoothly through even the most tortuous, diseased, and heavily calcified vessels²

.....Designed for PEVAR access

- ▶ **Perform minimally invasive PEVAR** with the ultra-low-profile 13F inner and 14F outer diameter delivery system featuring an integrated sheath introducer and state-of-the-art device compression technology^{2*}

Treatment for a broader range of patients

- ▶ **Demonstrated in simple and complex anatomies** including patients who would have been previously excluded from EVAR, even those with small (<7 mm), diseased, and challenging vessels^{2,3,6†}

Constructed to help reduce procedure complexity

- ▶ **Innovative INCRRAFT™ System technology**, including “cap-free” trans-renal design and peri-procedure customisation, enhances the capabilities of EVAR without adding complexity²

Engineered for ease of use

- ▶ **Use conventional delivery techniques**

Crafted to fit your needs



With custom deployment, optimised accuracy, and proven durability, you can free yourself from other device limitations and discover the benefits of the INCRAFT™ AAA Stent Graft System.



Proven, biodurable fabric

- ▶ **Seamlessly woven low-porosity polyester graft** is kink-resistant to help mitigate perfusion of the AAA sac^{2,4}

Accuracy assurance

- ▶ **Optimised placement accuracy**, proximally and distally, from the perpendicularly deployed aortic bifurcate that, with the aid of distinctive radiopaque proximal markers, can be partially repositioned prior to full deployment

Real-time customisation

- ▶ **In-procedure bilateral in situ adjustments** (3 cm on ipsilateral and 2 cm on contralateral side) of limb prostheses substantially improve placement accuracy and reduce the risk of inadvertent side-branch coverage²

Advanced graft stability


- ▶ **Mitigate migration** with the unique suprarenal fixation mechanism, featuring a flared laser-cut, trans-renal stent and integrated sharpened barbs for robust wall anchoring²

Enhanced stent-graft integrity

- ▶ **Biocompatible laser-cut nitinol stents**, which are sutured to the graft to minimise micro-motion²


Enduring modular junction strength

- ▶ **Durable polymer-free sealing technology** helps reduce disconnection and type III endoleaks—interlocking suture knots on the limb graft connect to the Z-stents on the inside of the aortic bifurcate legs²



The art of EVAR stands the test of time

No compromise in the durability of the AAA repair at 5 years^{6, 8†}



Freedom from device/procedure related MAE at 1 month: 100.0% (58/58) [93.8%, 100.0%]



Few-fit-most surgical graft concept⁷

Fewer units designed for in-procedure customisation deliver broad anatomical coverage through a wide range (3–6 mm) of oversizing—allowing you to streamline preoperative planning and inventory management.


- ▶ 4 aortic bifurcate diameters
- ▶ 19 iliac limb diameter sizes



Without compromising durability, the INCRRAFT™ AAA Stent Graft System delivers the clinical efficacy you require, as demonstrated through 5 years in the INNOVATION Trial.[±]




Mean AAA diameters at 1, 6, 12, and 60 months post-implantation¹



Proven aneurysm reduction at 5 years^{1†}

- ▶ 7.15 mm average sac diameter decrease
- ▶ Aneurysm sac enlargement (>5mm, %) is 8% (3/38) at 5 years

Case demonstration: Long-term clinical success through 4 years²



Reengineering the art of EVAR



Ultra-low-profile delivery (13F inner and 14F outer diameter) to simplify access, navigation, and deployment.¹




Customisable tri-modular design that leads to a tailored approach to EVAR.¹



Efficacy and durability without compromise demonstrated through 5 years in the INNOVATION Trial.²



Few-fit-most concept requires fewer units to optimise procedure planning and inventory management.¹



Talk to a Cordis representative about incorporating the INCRAFT™ AAA Stent Graft System into your EVAR programme.

The INCRAFT™ AAA Stent Graft System should only be used by physicians and teams trained in vascular interventional techniques, including training in the use of this device. Specific training expectations are described in the Instructions for Use. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification.

References: **1.** Torsello G, Brunkwall J, Scheinert D. Cordis INCRAFT™ ultra-low profile AAA stent-graft system. *J Cardiovasc Surg (Torino)*. 2011;52(5):661-667. **2.** Pratesi G. INCRAFT™ AAA Stent Graft System 2-year clinical data from the INNOVATION Trial. Presented at: Charing Cross International Symposium. April, 2014, London, UK. **3.** Chaikof EL, Fillinger MF, Matsumura JS. Identifying and grading factors that modify the outcome of endovascular aortic aneurysm repair. *J Vasc Surg*. 2002;35(5):1061-1066. **4.** Kannan RY1, Salacinski HJ, Butler PE, et al. Current status of prosthetic bypass grafts: a review. *J Biomed Mater Res B Appl Biomater*. 2005;74(1):570-581. **5.** Makaroun, M., Ouriel, K., Teigen, C., et al. (2019, June). 5-Year Results from the INCRAFT™ INSPIRATION Regulatory Study, Presented at the Society of Vascular Surgery (SVS) Vascular Annual Meeting in Maryland, USA. **6.** Cordis Data on File. 5 YR INNOVATION CSR. **7.** Pratesi G, Pratesi C, Chiesa R, Coppi G, Scheinert D, Brunkwall JS, Van der Meulen S, Torsello G. The INNOVATION Trial: four-year safety and effectiveness of the INCRAFT(TM) AAA Stent-Graft System for endovascular repair. *J Cardiovasc Surg (Torino)*. 2017 Oct;58(5):650-657. **8.** Torsello et. al, Aortoiliac remodeling and 5-year outcome of an ultralow-profile endograft. *Journal of Vascular Surgery*. June 2019, Volume 69, Issue 6, Pages 1747-1757.

* 15F inner and 16F outer diameter for the 34 mm aortic bifurcate.

† Ensure that femoral access vessels are adequate and compatible with vascular access techniques and accessories used with a 14F delivery profile.

± As demonstrated in clinical trials.

** 1 patient developed a late graft occlusion at day 666 treated with thrombectomy and bypass.

†† 1 death occurred within up to 1 year, 5 within the 2-year timeframe, all non-AAA related. All deaths were CEC adjudicated and confirmed to be unrelated to the device or to the procedure.

‡ 2 patients underwent re-intervention for the correction of a Type I EL at day 61 and 278.

For Healthcare Professionals Only. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification. Please contact your Cordis representative for additional product availability information. CORDIS, Cordis LOGO and INCRAFT are trademarks of Cardinal Health and may be registered in the US and/or in other countries. © 2020 Cardinal Health. All Rights Reserved. 100503885-2 06/2020

For more information please visit
www.cardinalhealth.co.uk

